Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julie Vose

Showing results (1-10 of 64) with videos related to

Pageof 7
Sort By:
Oncology (Williston Park, N.Y.)|September 21, 2021
Addressing Stress and Burnout in Hematology/Oncology PhysiciansJulie Vose
Clinical Advances in Hematology & Oncology : H&O|March 25, 2006
Personalized immunotherapy for the treatment of non-Hodgkin lymphoma: a promising approachJulie Vose
Oncology (Williston Park, N.Y.)|April 5, 2021
Minority Enrollment to Clinical Trials: Road to Increased AccessJulie Vose
Oncology (Williston Park, N.Y.)|February 12, 2021
WANTED: An "All-Out" National Vaccination ProgramHoward Hochster, Julie Vose
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2008
International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomesJulie Vose, James Armitage, Dennis Weisenburger, et al.
Cancer Biotherapy & Radiopharmaceuticals|November 25, 2003
Radioimmunotherapy: a novel treatment modality for B-cell non-Hodgkin's lymphomaMalik Juweid, Gerald L DeNardo, Michael Graham, et al.
Anti-Cancer Drugs|April 25, 2003
Aggressive lymphoma: improving treatment outcome with rituximabBertrand Coiffier, Michael Pfreundschuh, Rolf Stahel, et al.
The Oncologist|October 13, 2009
Radioimmunotherapy for stem cell transplantation in non-Hodgkin's lymphoma: in pursuit of a complete responseChristian Gisselbrecht, Julie Vose, Auayporn Nademanee, et al.
Seminars in Oncology|November 16, 2011
Early-stage Hodgkin disease in a 24-year-old womanChristopher Peters, Eli Glatstein, Julie Vose, et al.
International Immunopharmacology|December 3, 2022
Enrichment of innate immune cells from PBMC followed by triple cytokine activation for adoptive immunotherapyZaid Al-Kadhimi, Michael Callahan, Todd Fehniger, et al.
Pageof 7

Showing results (1-10 of 64) with videos related to

Sort By:
Pageof 7
Oncology (Williston Park, N.Y.)|September 21, 2021
Addressing Stress and Burnout in Hematology/Oncology PhysiciansJulie Vose
Clinical Advances in Hematology & Oncology : H&O|March 25, 2006
Personalized immunotherapy for the treatment of non-Hodgkin lymphoma: a promising approachJulie Vose
Oncology (Williston Park, N.Y.)|April 5, 2021
Minority Enrollment to Clinical Trials: Road to Increased AccessJulie Vose
Oncology (Williston Park, N.Y.)|February 12, 2021
WANTED: An "All-Out" National Vaccination ProgramHoward Hochster, Julie Vose
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2008
International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomesJulie Vose, James Armitage, Dennis Weisenburger, et al.
Cancer Biotherapy & Radiopharmaceuticals|November 25, 2003
Radioimmunotherapy: a novel treatment modality for B-cell non-Hodgkin's lymphomaMalik Juweid, Gerald L DeNardo, Michael Graham, et al.
Anti-Cancer Drugs|April 25, 2003
Aggressive lymphoma: improving treatment outcome with rituximabBertrand Coiffier, Michael Pfreundschuh, Rolf Stahel, et al.
The Oncologist|October 13, 2009
Radioimmunotherapy for stem cell transplantation in non-Hodgkin's lymphoma: in pursuit of a complete responseChristian Gisselbrecht, Julie Vose, Auayporn Nademanee, et al.
Seminars in Oncology|November 16, 2011
Early-stage Hodgkin disease in a 24-year-old womanChristopher Peters, Eli Glatstein, Julie Vose, et al.
International Immunopharmacology|December 3, 2022
Enrichment of innate immune cells from PBMC followed by triple cytokine activation for adoptive immunotherapyZaid Al-Kadhimi, Michael Callahan, Todd Fehniger, et al.
Pageof 7